Tenax Therapeutics, Inc. (NasdaqCM: TENX)
Health Care · Biotechnology · US
$1.63
-13.10% today · -74.9% 1Y
Tenax Therapeutics, Inc. (NasdaqCM: TENX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $107.12M and employs 15 people.
Over the last twelve months the share price has lost 74.9%, trading between 1.31 and 19.40.
Tweenvest scores Tenax Therapeutics, Inc. across four factors: quality 51/100, value 48/100. Its strongest factor is quality.
TENX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $107.12M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.47
- Dividend yield
- —
- Beta (5Y)
- 0.92
- 52-week high
- $19.40
- 52-week low
- $1.31
- Avg volume (3M)
- —
- Shares outstanding
- 57.28M
- Employees
- 15
- Next earnings
- —
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
- ISIN
- US88032L6056
- Founded
- 1967
- Listed since
- Apr 4, 1994
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Great Novel Therapeutics Biotech & MedicalsTPEX: 7427 | $109.39M | NT$66.10 | -5.97% |
| Pharmosa Biopharm Inc.TPEX: 6875 | $109.08M | NT$27.00 | -9.70% |
| Immunic, Inc.NasdaqCM: IMUX | $108.47M | $6.92 | -12.96% |
| Humacyte, Inc.NasdaqGS: HUMA | $108.23M | $0.36 | -8.21% |
| Maxigen Biotech Inc.TWSE: 1783 | $106.88M | NT$38.10 | +2.83% |
| Tevogen Inc.NasdaqGM: TVGN | $106.69M | $7.15 | +5.46% |
| Vaxart, Inc.OTCPK: VXRT | $105.65M | $0.43 | -0.59% |
| BioGend Therapeutics Co., Ltd.TPEX: 6733 | $104.60M | NT$24.90 | -0.80% |
Figures last refreshed Oct 11, 2026.